Jacenik D, Fichna J. Treatment strategy and therapy based on immune response in patients with gastric cancers. World J Gastrointest Surg 2024; 16(8): 2393-2395 [PMID: 39220051 DOI: 10.4240/wjgs.v16.i8.2393]
Corresponding Author of This Article
Damian Jacenik, PhD, Assistant Professor, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland. damian.jacenik@biol.uni.lodz.pl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Aug 27, 2024; 16(8): 2393-2395 Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2393
Treatment strategy and therapy based on immune response in patients with gastric cancers
Damian Jacenik, Jakub Fichna
Damian Jacenik, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz 90-236, Poland
Jakub Fichna, Department of Biochemistry, Medical University of Lodz, Lodz 92-215, Poland
Author contributions: Jacenik D and Fichna J wrote, reviewed and edited the manuscript; Jacenik D wrote the original draft and conceptualised the manuscript.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Damian Jacenik, PhD, Assistant Professor, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland. damian.jacenik@biol.uni.lodz.pl
Received: April 3, 2024 Revised: May 7, 2024 Accepted: June 4, 2024 Published online: August 27, 2024 Processing time: 135 Days and 8.9 Hours
Abstract
In this editorial, we highlight the significance of a retrospective study “Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis” performed by Liu et al. The authors utilized data collected from gastric cancer (GC) patients and assessed immunotherapy effectiveness and survival status. They found significant differences in treatment response. Because immunotherapy seems to be a beneficial strategy for advanced GC patients, stratification of the data based on metastasis status may further improve treatment strategies.
Core Tip: Gastric cancer (GC) is a highly heterogenous disease that affects patients’ outcomes. Immunotherapy in GC patients seems to provide several clinical benefits, and retrospective studies are needed to evaluate immunotherapy efficiency and safety. The aim of this editorial is to provide a short and informative introduction elaborating the efficiency and safety of immunotherapy in patients with advanced GCs manifested by absence or presence of liver metastasis.
